Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY4005130 for adults with non-segmental vitiligo
2025-524726-18-00Phase 2Authorised
- Sponsor
- Eli Lilly and Company
- Start
- Jul 2026
- Countries
- 5
01
Overview
Phase 2, randomised, double-blind trial in Vitiligo comparing LY4005130 with Placebo (2 arms). Primary endpoint: Percentage of participants achieving Facial Vitiligo Area Scoring Index 75. Planned start Jul 2026; status: authorised.
02
Drugs
LY4005130
03
Conditions
Vitiligo
Beyond the preview
Go deeper on 2025-524726-18-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524726-18-00.